GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » Tax Expense

China Isotope & Radiation (HKSE:01763) Tax Expense : HK$160 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation Tax Expense?

China Isotope & Radiation's tax expense for the months ended in Dec. 2023 was HK$87 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$160 Mil.


China Isotope & Radiation Tax Expense Historical Data

The historical data trend for China Isotope & Radiation's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation Tax Expense Chart

China Isotope & Radiation Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only 121.16 143.01 158.74 184.88 160.03

China Isotope & Radiation Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.28 83.84 105.01 73.20 86.83

China Isotope & Radiation Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$160 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Isotope & Radiation  (HKSE:01763) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


China Isotope & Radiation Tax Expense Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


China Isotope & Radiation (HKSE:01763) Business Description

Traded in Other Exchanges
N/A
Address
No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines